CSL Seqirus Expands U.S. Flu Vaccine Supply After Early Finish to 2026/27 Campaign

CSL Seqirus, a unit of CSL (CSL.AX), said Sept. 29 it expanded U.S. influenza vaccine availability after completing its 2026/27 manufacturing campaign ahead of schedule, with most customer orders shipped and remaining deliveries due early. The move follows reported supply challenges in parts of the U.S. and global flu vaccine market after three WHO-recommended strain changes for the coming season. The company said it implemented the strain changes despite added manufacturing complexity and holds additional doses for public health efforts. CSL.AX traded at AUD 182.30, up 0.21%.